Brind.

Ocugen announced a regional partnership for OCU400 in Korea.

1 report, 1 independent Updated Aug 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Ocugen announced a regional partnership for OCU400 in Korea.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Ocugen secured exclusive Korean rights for OCU400, and FDA concurrence was granted, enabling BLA submission.Sub-event
  2. Ocugen forms a regional partnership for OCU400 in Korea.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • GuruFocus.comOcugen Inc (OCGN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges Cash Equivalents and Restricted Cash: $27.3 million as of June 30, 2025, compared to $58.8 million as